Clinical Trial Update: Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating different doses and schedules of milatuzumab (hLL1) in patients with chronic lymphocytic leukemia/lymphoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Chronic Lymphocytic Lymphoma

Drugs mentioned

• Milatuzumab (milatuzumab)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: COMPLETED